Reviewed by Wesley Hardin, PA-C — Licensed Montana Physician Associate
What Is Foundayo®?
Foundayo® (orforglipron) is an FDA-approved, once-daily oral GLP-1 receptor agonist for chronic weight management. Manufactured by Eli Lilly — the same company behind Zepbound® (tirzepatide) — Foundayo® represents a major advancement because it's a pill, not an injection.
As a non-peptide, small-molecule GLP-1 agonist, Foundayo® can be taken orally at any time of day without the food and water restrictions required by other oral GLP-1 options. This makes it a potentially more convenient choice for patients who prefer not to use injectable medications.
How Foundayo® Works
Like other GLP-1 medications, Foundayo® works by mimicking the GLP-1 hormone to:
- Reduce appetite by acting on hunger signals in the brain
- Slow gastric emptying, helping you feel fuller longer
- Support blood sugar regulation
- Promote sustained caloric reduction without extreme dieting
What makes Foundayo® unique is its small-molecule structure, which allows it to be absorbed orally without degradation in the digestive system — a limitation that previously restricted most GLP-1 medications to injectable formats.
Clinical Evidence: The ATTAIN-1 Trial
The efficacy of Foundayo® was demonstrated in the ATTAIN-1 phase 3 clinical trial:
Adults taking the highest dose of Foundayo® lost an average of 27 pounds (approximately 12.4% of body weight) over 72 weeks when combined with a reduced-calorie diet and increased physical activity.
The trial also demonstrated improvements in key cardiometabolic risk factors. As with all weight loss medications, individual results vary and depend on factors including adherence, lifestyle changes, and baseline health status.
Foundayo® vs. Injectable GLP-1 Medications
Montana residents now have three FDA-approved GLP-1 weight loss medication options through PeakHealth MT:
| Feature | Foundayo® | Wegovy® | Zepbound® |
|---|---|---|---|
| Generic Name | Orforglipron | Semaglutide | Tirzepatide |
| Administration | Daily pill | Weekly injection | Weekly injection |
| Drug Class | GLP-1 RA | GLP-1 RA | GIP + GLP-1 RA |
| Food Restrictions | None | N/A (injection) | N/A (injection) |
| Avg. Weight Loss | ~12% at 72 wks | ~15% at 68 wks | ~22% at 72 wks |
| Manufacturer | Eli Lilly | Novo Nordisk | Eli Lilly |
Weight loss percentages are based on published clinical trial data and represent averages. Individual results will vary. Learn more about the differences in our semaglutide vs. tirzepatide comparison.
Who Is a Good Candidate for Foundayo®?
You may be a candidate for Foundayo® if you:
- Have a BMI ≥ 30 (obesity)
- Have a BMI ≥ 27 with at least one weight-related condition (type 2 diabetes, high blood pressure, high cholesterol)
- Prefer a daily pill over weekly injections
- Want a medication without food or water timing restrictions
As with all GLP-1 medications, Foundayo® carries a boxed warning about thyroid C-cell tumor risk. It is not appropriate for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your clinician will review your complete medical history during your initial consultation.
How Foundayo® Is Prescribed
Foundayo® uses a gradual dose titration schedule to minimize side effects:
- Starting dose is low and increased incrementally
- Available in multiple tablet strengths (0.8 mg through 17.2 mg)
- Taken once daily at any time — with or without food
- No water restrictions before or after taking the pill
Your clinician will determine the appropriate titration schedule based on your tolerance and response. Regular follow-up visits ensure dosing is optimized for your goals.
Foundayo® Available Across Montana via Telemedicine
PeakHealth MT provides Foundayo® evaluations for residents statewide through secure telemedicine, including:
Whether you prefer Foundayo® (oral pill), Wegovy® (semaglutide injection), or Zepbound® (tirzepatide injection), your clinician will help you choose the best option for your health profile and lifestyle.
What to Expect from Foundayo® Treatment
- Comprehensive medical consultation via secure video
- Required baseline laboratory evaluation
- Gradual dose titration to optimize results and minimize side effects
- Regular follow-up visits for monitoring
- Electronic prescription sent to your preferred pharmacy
Learn more about common GLP-1 side effects and how long GLP-1 medications take to work.
Results vary by individual. Foundayo® is not appropriate or necessary for everyone. All treatment decisions are made by your licensed Montana clinician after a thorough evaluation.
